- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01284153
Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study
June 28, 2024 updated by: Universitaire Ziekenhuizen KU Leuven
A Comparison of Three Radiotherapy Techniques for Breast Cancer: a Planning Study
This study has the purpose to investigate the benefit of treating breast cancer patients in prone position.
This treatment is compared to the standard technique in our center (supine position with or without respiratory gating).
The investigators want to compare the doses on the organs at risk (heart and lungs) in the different techniques.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Caroline Sweldens, Doctor
- Phone Number: 003216347600
- Email: caroline.sweldens@uzleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- UZ Leuven Radiotherapy Department
-
Contact:
- Caroline Sweldens, Doctor
- Phone Number: 003216347600
- Email: caroline.sweldens@uzleuven.be
-
Sub-Investigator:
- Caroline Sweldens, Doctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients who have an indication for radiotherapy of the breast and/or the lymph nodes.
Description
Inclusion Criteria:
- indication for radiotherapy of the breast and /or lymph nodes
Exclusion Criteria:
- none ( planning study)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Caroline Sweldens, Doctor, UZ Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2011
Primary Completion (Estimated)
October 1, 2025
Study Completion (Estimated)
October 1, 2025
Study Registration Dates
First Submitted
January 24, 2011
First Submitted That Met QC Criteria
January 25, 2011
First Posted (Estimated)
January 26, 2011
Study Record Updates
Last Update Posted (Actual)
July 1, 2024
Last Update Submitted That Met QC Criteria
June 28, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S52869
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Cancer | Breast Carcinoma | Malignant Neoplasm of Breast | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCCompletedBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Massachusetts General HospitalMassachusetts Institute of TechnologyNot yet recruitingBreast Cancer | Breast Asymmetry | Breast Abnormalities | Breast LesionUnited States
-
Xijing HospitalActive, not recruitingBreast Cancer | Breast Cancer (Triple Negative Breast Cancer (TNBC))China
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States